Loading the records…
Loading the records…
The SUPER BUGS Act (HR7879) is a procedural bill with zero funding, no procurement mechanism, and no regulatory impact. It requires the State Department to develop a strategy for international pandemic product collaboration. Market impact is negligible — recent price moves in $PFE (-1.41% 7d), $MRNA (-7.27% 7d), $JNJ (+1.01% 7d), and $GILD (+0.18% 7d) reflect broader sector trends, not this legislation.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
No actionable market implications from this bill. Retail investors should ignore HR7879 as a trading catalyst. Current prices: $MRNA at $47.04 (52-wk range $22.28 - $59.55) with -7.27% weekly decline reflects broader biotech weakness. $PFE, $JNJ, and show no abnormal volume or price action tied to this legislation. Focus on FDA decisions, earnings, and pipeline catalysts for these names instead.
The SUPER BUGS Act (HR7879), introduced March 9, 2026, is a procedural bill requiring the Secretary of State, in consultation with HHS, to formulate a strategy for securing international support for pandemic product development. The bill is in early committee stage — referred to the House Foreign Affairs Committee — with only 2 cosponsors (Reps. Levin and Valadao). It authorizes zero funding, mandates no procurement, and creates no regulatory changes. The bill's text is a reporting requirement: the administration must produce a strategy document. No money flows to any company.
From a legislative process standpoint, this bill faces a long path: it needs committee markup, House passage, Senate introduction/passage, and Presidential action. The sponsor is a junior member (Rep. Levin, D-CA), and there is no companion bill in the Senate. Procedural bills like this often die in committee. Even if passed, a strategy document has no binding effect on government procurement or private sector activity.
Market data confirms no bill-related impact. $MRNA has dropped -7.27% over the past week to $47.04, driven by broader sector weakness in biotech and lack of near-term catalyst for its COVID/RSV pipeline. $PFE fell -1.41% in the same period. $JNJ (+1.01%) and (+0.18%) have been relatively stable. These movements are consistent with sector trends, not legislative action.
The tickers listed ($PFE, $MRNA, $JNJ, ) are included for completeness — they are the largest US pandemic product developers. However, the causal chain is entirely procedural. This bill creates no new revenue opportunities, no cost burdens, and no competitive advantages. The correct assessment is neutral with negligible impact.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Requires State Department to formulate a strategy for international collaboration on pandemic product development; no funding, no procurement, no regulatory change.
Who must act
Secretary of State, in consultation with HHS — no private sector entity is obligated.
What happens
No direct economic consequence on any private entity; the bill is a procedural reporting requirement with zero appropriations.
Stock impact
PFE's pandemic product revenue (Comirnaty, Paxlovid) is driven by public health emergencies and procurement contracts, not this non-binding strategy document. No revenue impact.
What the bill does
Same as above — strategy formulation only; no funding, procurement, or mandate.
Who must act
Secretary of State, in consultation with HHS — no private sector entity is obligated.
What happens
No direct economic consequence; the bill does not authorize any spending or create any market for mRNA products.
Stock impact
MRNA's revenue depends on COVID-19 vaccine sales and RSV/other pipeline approvals. This bill creates no new demand, no procurement guarantees, and no regulatory pathway. No revenue impact.
Matched on shared policy language across AI analyses, with ticker & timing weight
Protecting Free Vaccines Act of 2025
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Growing and Preserving Innovation in America Act of 2025
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
Price Gouging Prevention Act of 2025
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
ADVANCED TECHNOLOGY INTERNATIONAL: $19.6M Department of Health and Human Services Contract
Protecting Free Vaccines Act
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →